As more and more 'normal' people are having their genomes sequenced and published, especially as part of the normal counterpart to a cancer genome, there is the question of what else you can do with this information. If it is published and downloadable, what obstacles are there to stop a public spirited researcher letting that data become part of the 1000 genomes project. It would squeeze extra use out of the data, and would improve the numbers of the 1000 genomes. Just wondering really.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...